注射雷珠单抗联合810 nm激光对Ⅱ区早产儿视网膜病变患儿的影响  

The Impact of Intravitreal Ranibizumab Combined with 810 nm Laser on Retinopathy of Prematurity in Zone Ⅱ Premature Infants

作　　者：徐利辉 孙爽[1] 卢跃兵 黄云云[1] 蒋瑜[1] 史丽英 XU Lihui;SUN Shuang;LU Yuebing;HUANG Yunyun;JIANG Yu;SHI Liying(Department of Ophthalmology,Henan Children's Hospital,Zhengzhou University Affiliated Zhengzhou Children's Hospital,Zhengzhou Henan 451161,China)

机构地区：[1]河南省儿童医院,郑州大学附属郑州儿童医院眼科,河南郑州451161

出　　处：《临床研究》2024年第5期13-15,共3页Clinical Research

摘　　要：目的 研究注射雷珠单抗联合810 nm激光对Ⅱ区早产儿视网膜病变(ROP)病变控制率及血清血管内皮生长因子(VEGF)的影响。方法 以2020年1月至2023年6月河南省儿童医院收治的50例(90眼)Ⅱ区ROP患儿临床资料进行回顾性分析,根据治疗方案将患儿分为对照组(25例,46眼)和联合组(25例,44眼)。对照组采用注射雷珠单抗治疗,联合组采用注射雷珠单抗联合810 nm激光光凝治疗。比较两组病变控制率,治疗后6个月视网膜发育功能指标[全视野闪光视网膜电图(FERG)明、暗适应的b波的振幅],治疗前及治疗后1个月荧光素眼底血管造影(FFA)表现、血清血管内皮生长因子(VEGF)水平。结果 联合组病变控制率(93.18%)高于对照组(78.26%),差异有统计学意义(P <0.05);治疗后1个月,联合组荧光素渗漏减少率、新生血管消退率及视网膜血管扩张迂曲好转率均高于对照组,差异有统计学意义(P <0.05);治疗后6个月,联合组FERG明、暗适应b波振幅均高于对照组,差异有统计学意义(P <0.05);治疗后1个月,联合组血清VEGF水平低于对照组,差异有统计学意义(P <0.05)。结论 采用雷珠单抗联合810 nm激光光凝治疗可有效促进Ⅱ区ROP患儿FFA表现及视网膜发育功能改善,抑制VEGF表达,提高病变控制率。Objective To investigate the effect of intravitreal ranibizumab combined with 810 nm laser on the control rate of retinopathy of prematurity(ROP) in zone Ⅱ premature infants and the level of serum vascular endothelial growth factor(VEGF).Methods A retrospective analysis was conducted on clinical data of 50 cases(90 eyes) of zone Ⅱ ROP infants admitted to Henan Children's Hospital from January 2020 to June 2023.According to the treatment plan,the infants were divided into a control group(25 cases,46 eyes) and a combination group(25 cases,44 eyes).The control group received intravitreal ranibizumab treatment,while the combination group received intravitreal ranibizumab combined with 810 nm laser photocoagulation treatment.The control rates of lesions,retinal development functional indicators [full-field electroretinogram(FERG) amplitude of the b-wave in light and dark adaptation],fluorescein fundus angiography(FFA) findings before and 1 month after treatment,and serum VEGF levels were compared between the two groups.Results The lesion control rate in the combination group(93.18%) was higher than that in the control group(78.26%),with a statistically significant difference(P < 0.05).One month after treatment,the combination group showed higher rates of reduction in fluorescein leakage,regression of neovascularization,and improvement in retinal vessel tortuosity compared to the control group,with statistically significant differences(P < 0.05).Six months after treatment,the combination group had higher FERG b-wave amplitudes in light and dark adaptation than the control group,with statistically significant differences(P < 0.05).One month after treatment,the serum VEGF level in the combination group was lower than that in the control group,with a statistically significant difference(P < 0.05).Conclusion Intravitreal ranibizumab combined with 810 nm laser photocoagulation treatment can effectively promote the improvement of FFA manifestations and retinal development function in zone Ⅱ ROP infants,inhibit VEGF exp

关 键 词：早产儿视网膜病变 雷珠单抗 810 nm激光 疾病控制率 

分 类 号：R722.6[医药卫生—儿科]